Pharmaceutical

NBE Therapeutics opens ADC research facility in Switzerland

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, Switzerland.

Apr 4, 2025 - 06:00
NBE Therapeutics opens ADC research facility in Switzerland
Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, Switzerland.
Read the original article

Tags:

Previous Article

New Sea Grant Report Aids Great Lakes Fish Farmers in Understanding Aquaculture ...

Next Article

Digital cognitive assessments and blood-based biomarkers in Alzheimer’s research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard

STAT+: Pharmalittle: End of biotech’s stock market mala...

Sep 26, 2023

NCCN visits Vietnam in continued cancer care collaboration

NCCN visits Vietnam in continued cancer care collaboration

Nov 3, 2024

Machine learning adoption into supply chain management on the horizon

Machine learning adoption into supply chain management ...

Mar 5, 2025